349 related articles for article (PubMed ID: 18669012)
1. Low molecular weight heparins in patients with renal insufficiency.
Symes J
CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
[TBL] [Abstract][Full Text] [Related]
2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
Clark NP
Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
[TBL] [Abstract][Full Text] [Related]
5. [Thrombosis prophylaxis with heparins in intensive care patients].
Greinacher A; Janssen D
Anasthesiol Intensivmed Notfallmed Schmerzther; 2005 Mar; 40(3):156-63. PubMed ID: 15770559
[TBL] [Abstract][Full Text] [Related]
6. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
7. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
George-Phillips KL; Bungard TJ
Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin and bleeding in patients with chronic renal failure.
Crowther M; Lim W
Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
[TBL] [Abstract][Full Text] [Related]
11. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies.
Sagedal S; Hartmann A
Eur J Med Res; 2004 Mar; 9(3):125-30. PubMed ID: 15096322
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
14. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry.
Hammerstingl C; Schmitz A; Fimmers R; Omran H
Cardiovasc Ther; 2009; 27(4):230-8. PubMed ID: 19903186
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.
Pruemer J
Semin Oncol; 2006 Apr; 33(2 Suppl 4):S26-39; quiz S41-2. PubMed ID: 16638458
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
17. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency.
Lim W; Al Saleh K; Douketis JD
Thromb Res; 2006; 118(3):409-16. PubMed ID: 16026817
[TBL] [Abstract][Full Text] [Related]
19. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
20. The use of unfractionated heparin and low molecular weight heparins in pregnancy.
Casele HL
Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
